Allergen grabs $80M round for late-stage food allergy R&D; Kythera raises $125M;

@FierceBiotech: Acadia craters as takeover buzz is silenced by news of an unexpected NDA delay, CEO exit. Article | Follow @FierceBiotech

@JohnCFierce: 4 of the last Fierce 15 have filed IPOs since last fall. More coming. Hot market, eh? Feature | Follow @JohnCFierce

@DamianFierce: Here's the $ENDP letter to $SLXP's board, pitching a deal that's 74% stock. PDF | Follow @DamianFierce

> San Mateo, CA-based Allergen Research Corporation, a food allergy biotech, says it snagged an $80 million Series B financing. Foresite Capital led the round, with participation from existing investor Longitude Capital and new investors Fidelity Management & Research Company, Aisling Capital, Adage Capital, RA Capital Management and Palo Alto Investors. The money will fuel a Phase III clinical trial of ARC's lead product, AR 101, a "standardized, pharmaceutical-grade peanut protein formulation for treating peanut allergy via characterized oral desensitization immunotherapy." The company also plans to begin clinical trials for treatment of egg and milk allergies in the coming year. Release

> Following up fast on a positive adcomm vote for its chin-fat therapy, Kythera raised $125 million. Release

> Tetraphase Pharmaceuticals ($TTPH) raised $150 million in a stock offering. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Brain-controlled, robotic prosthetic hand comes closer to simulating reality. Article | Follow @FierceMedDev

@VarunSaxena2: Irish research center wins EU funding to study and develop transdermal delivery methods. More from FierceDrugDelivery | Follow @VarunSaxena2

@EmilyWFierce: Some background info on liquid biopsies. More from MIT Technology Review | Follow @EmilyWFierce

> LifeMap CEO: Apple's ResearchKit 'unshackles science.' More

> Scientists tout positive results for Alzheimer's ultrasound therapy in mice. Article

> Startup raises $3.9M to market device-app combo to calm panic disorder. Report

Pharma News

@FiercePharma: Gates Foundation puts $52 million behind CureVac, following Sanofi, Boehringer's lead. FierceVaccines story | Follow @FiercePharma

@EricPFierce: Texas drug compounder corralled by federal injunction. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Should Teva buy Mylan? 'Close call,' analyst says. Report | Follow @CarlyHFierce

> Endo aims to lure Salix from Valeant with $175-per-share offer. Report

> J&J boosts CEO pay to $25M, doubles R&D chief's haul. Article

Vaccines News

> Analyst: Ebola vaccine developers 'need to weigh risks' as cases dwindle. More

> Combo-happy Diamyd launches new diabetes vaccine trial in children. Report

> Smallpox vaccine helps Bavarian Nordic net first full-year profit in 5 years. Story

> Takeda transfers HPV vaccine rights as it continues globalization push. More

> Bharat's $1 rotavirus vaccine rolls out in India to challenge GSK, Merck. Article

Pharma Manufacturing News

> Hikma profits soften as shortages of doxycycline are resolved. Article

> Mylan recalls drug after problem uncovered with Indian supplier. Item

> Texas compounder corralled by federal injunction. More

> Pfizer makes it official, it has reversed its decision to close Irish Lipitor plant. Story

> Manufacturing mess at J&J consumer plant results in guilty plea, $20M fine. Report

Pharma Asia News

> AstraZeneca and Singapore's A*STAR ink research pact on complex heart failure syndrome. More

> Biotech in China is built brick-by-brick, but more money would help, BeiGene's Oyler says. Article

> First off the blocks, Natco gets India's regulatory nod for hep C copy. Story

> Japan a lucrative market for endocrine sales, report says. Item

> Glaxo plants a flag in Singapore with CEO Witty on hand. Report

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.